Loading...
During the past 10 to 15 years, as prostate-specific antigen (PSA) screening has become the de facto standard of care in the U.S., we have witnessed a steep rise in the number of prostate cancer diagnoses, particularly for organ-confined disease. Notwithstanding the “successes” of PSA screening, approximately 20% to 30% of patients who undergo curative-intent local therapy demonstrate PSA progression. In selected high-risk patients, multimodal approaches — such as androgen-deprivation therapy (ADT) plus external beam radiotherapy (EBRT) — have been associated with better outcomes than have monotherapy regimens. However, data regarding the effects of multimodal therapy on health-related quality of life (QOL) are limited.
To shed light on this…